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Alzheimer’s disease (AD) is recognized as a major health hazard that mostly affects people
older than 60 years. AD is one of the biggest medical, economic, and social concerns to
patients and their caregivers. AD was ranked as the 5th leading cause of global deaths in
2016 by the World Health Organization (WHO). Many drugs targeting the production,
aggregation, and clearance of Ab plaques failed to give any conclusive clinical outcomes.
This mainly stems from the fact that AD is not a disease attributed to a single-gene
mutation. Two hallmarks of AD, Ab plaques and neurofibrillary tangles (NFTs), can
simultaneously induce other AD etiologies where every pathway is a loop of
consequential events. Therefore, the focus of recent AD research has shifted to
exploring other etiologies, such as neuroinflammation and central hyperexcitability.
Neuroinflammation results from the hyperactivation of microglia and astrocytes that
release pro-inflammatory cytokines due to the neurological insults caused by Ab
plaques and NFTs, eventually leading to synaptic dysfunction and neuronal death. This
review will report the failures and side effects of many anti-Ab drugs. In addition, emerging
treatments targeting neuroinflammation in AD, such as nonsteroidal anti-inflammatory
drugs (NSAIDs) and receptor-interacting serine/threonine protein kinase 1 (RIPK1), that
restore calcium dyshomeostasis and microglia physiological function in clearing Ab
plaques, respectively, will be deliberately discussed. Other novel pharmacotherapy
strategies in treating AD, including disease-modifying agents (DMTs), repurposing of
medications used to treat non-AD illnesses, and multi target-directed ligands (MTDLs) are
also reviewed. These approaches open new doors to the development of AD therapy,
especially combination therapy that can cater for several targets simultaneously, hence
effectively slowing or stopping AD.
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Alzheimer's disease (AD) is a chronic neurodegenerative disease
that usually affects people older than 60 years. The etiologies of
many neurodegenerative diseases are not limited to a single gene
or pathway, but are rather an intricate network of causatives,
including neuroinflammation, oxidative stress, mitochondrial
dysfunction, protein misfolding, and aggregation that can lead
to cell death (Wu et al., 2018; Kamil et al., 2019). Various
mechanisms were associated with the sporadic form of AD,
which accounts for most AD cases, whereas mutations of three
genes, including amyloid precursor protein (APP), presenilin 1
(PS1), and presenilin 2 (PS2) are heavily linked with familial AD
cases (Newman et al., 2017). The irreversible symptoms of AD,
such as progressive deterioration of intellect, memory, and
attentiveness, are noticeable when both NFTs and Ab plaques
have disseminated through the limbic system (Canter et al., 2016).
Ab plaques-induced brain atrophy begins with the loss of
synapses and enlargement of the ventricles (Ramos-Rodriguez
et al., 2017), whereas NFTs are often associated with grey matter
loss (Bejanin et al., 2017). Progressive loss of cortical interneurons
and specific neurotransmitter pathways such as acetylcholine
(ACh), noradrenaline (NA), and serotonin (5-HT) are also
reported in AD (Ribeiro et al., 2017). In the early stages of AD,
typically around age 70, cells in the hippocampus start to
degenerate, causing mild forgetfulness of recent events and
familiar names, and also difficulty in solving simple mathematical
problems (Selkoe, 2011; Bie et al., 2018). After 10 years, atrophy of
the cerebral cortex occurs in moderate AD stage, resulting in a
decline in language, emotional outbursts, impaired ability in
conducting simple tasks such as combing hair and buttoning
shirts, and an inability to think clearly. In advanced stages of AD,
where more nerve cells have undergone degeneration, patients are
often agitated, wandering, and unable to recognize faces and
communicate (Braak and Tredici, 2018).
AD-related deaths have markedly increased over the past two
decades, but a cure remains elusive (Alzheimer's Association, 2019).
Treatment options for AD that are approved by the Food and Drug
Administration (FDA) do not have a curative effect or are able to
slow down the progression of the disease (Folch et al., 2018a). The
most commonly prescribed drugs are acetylcholinesterase inhibitors
(AChEIs), such as tacrine, donepezil, rivastigmine, and galantamine,
and N-methyl-D-aspartate receptor (NMDAr) antagonists, such as
memantine (Morsy and Trippier, 2018; Table 1). Tacrine was
eventually discontinued due to its hepatotoxicity, and tacrine
hybrids are now being studied (Sameem et al., 2017). AChEIs
delay the metabolism of ACh by inhibiting acetylcholinesterase
(AChE) as AD patients have a deficiency of ACh (Kumar et al.,
2015). Meanwhile, memantine prevents excitotoxicity by blocking
NMDAr's activation (Marttinen et al., 2018).
Heterogeneity in AD pathogenesis impedes the development
of curative strategies. Three neuropathological mechanisms
postulated in AD are: i) formation of extracellular Ab plaques
by insoluble amyloid proteins' aggregate, ii) formation of NFTs
(disorganized bundles offilaments in the neuronal cytoplasm) by
hyperphosphorylated tau proteins, and iii) neuronal loss as the
aftermath of the Ab plaques and NFTs (Revett et al., 2013). Thus,Frontiers in Pharmacology | www.frontiersin.org 2many drugs failed to improve cognition in mild-to-moderate AD
patients as the drugs target a single pathology without
acknowledging other neurological insults (Jobke et al., 2018).
Hence, a multi-target approach is being highly investigated in
clinical trials to synergistically target distinct pathways and
ameliorate AD (Cummings et al., 2019).AMYLOID PLAQUES
Overproduction and reduced clearance of Ab42 monomers cause
the deposition of Ab plaques that eventually leads to alteration in
downstream neurobiological events (Takahashi et al., 2017). Ab
plaques cause catastrophic damage to cellular membranes'
integrity through the formation of the membrane's pore and
the reduction of the membrane's fluidity, hence, leading to
neuronal death (Yasumoto et al., 2019). Ab plaques also trigger
the activation of microglia and astrocyte as an inflammatory
response, alter the neuronal calcium homeostasis causing oxidative
injury, and disrupt the protein kinase and phosphatase-related
pathways, resulting in hyperphosphorylation of tau and formation
of NFTs (Reiman, 2016). Furthermore, self-propagation of Ab42
plaques and hyperphosphorylated tau, via a prion-like mechanism,
may exaggerate the synaptic dysfunction, neurotransmitter deficits,
and neuronal loss in the brain (Goedert, 2015).
Although Ab plaques alone may not be adequate in causing
the transmission of pathological tau, amyloid cascade hypothesis
suggests that deposition Ab plaques is the triggering factor for
the cognitive deteriorations in AD (Blennow et al., 2015). Hence,
future drug development should seek to determine whether a
single-target therapy targeting Ab is sufficient to treat AD or
whether a combination therapy between anti-Ab and anti-tau is
needed (He et al., 2018).NEUROFIBRILLARY TANGLES
Intracellular NFTs are the deposits of insoluble proteins in
neuronal cell bodies (Vanden Dries et al., 2017). Tau is a
cytoskeletal microtubule-associated protein (MAP) that is
phosphorylated at three sites - serine (S), threonine (T), and at
residues adjacent to proline - and binds at the microtubules
(MTs) to sustain the MTs' stability and integrity (Pradeepkiran
et al., 2019). The toxicity of tau can impair neuronal function
depending on its post-translational modifications. The most
potent phosphorylations of tau take place at T231, S235, and
S262, which results in the loss of tau's ability to bind to MTs,
leading to tau self-assembly into paired helical filaments (PHF)
(Iqbal et al., 2018).
Phosphorylation of tau detaches it from MTs to allow the
intracellular transportation of subcellular organelles such as
mitochondria and lysosomes from the nerve terminals to the
cells' soma through secretory vesicles (Pradeepkiran et al., 2019).
Hyperphosphorylation of tau sequesters the normal tau in which
it may excessively impair tau binding and destabilize MTs, thus,
impairing the axonal transport causing neurodegenerationMarch 2020 | Volume 11 | Article 261
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death (Minjarez et al., 2013). Hyperphosphorylated tau tends to
misfold and forms PHF which eventually aggregates to form
NFTs as a defense mechanism in the cell soma (Gandini
et al., 2018).
In contrast to Ab pathology, which causes hyperactivity of
neurons, tau silences the neurons (Busche et al., 2019). This
provokes the question on how the coexistence of Ab and tau
pathologies causes neurodegeneration in AD. From the fully
eradicated neuronal hyperactivity and drastic decline of cortical
activity in rats with both Ab and tau pathologies, it can be
concluded that deposition of Ab plaques may be the triggering
factor that sparks other AD etiologies, but tau pathology is the
one dominating the aftermath effects of this dual proteinopathies
in AD. It is tau pathology that determines the cognitive status in
AD compared to Ab pathology, which is another solid reason for
the constant failures of Ab drugs. The combination of anti-
amyloid and anti-tau is crucial, as suppressing gene expression of
tau is less effective in restoring the neuronal impairments in the
presence of Ab plaques (DeVos et al., 2018).CURRENT DRUGS TARGETING
Ab - FAILURES
According to the updated AD drug development pipeline in
2018, although more than 50% of drugs in Phase III trials are
targeting Ab, there is still a steep 40% decline from year 2017 to
2018 in anti-Ab drugs in Phase I and II trials, which manifests
the shift in AD research following the repetitive failures of anti-Frontiers in Pharmacology | www.frontiersin.org 3Ab drugs (Mullane and Williams, 2018) (Table 2). Reducing the
generation of Ab42, inhibiting the aggregation of Ab plaques, or
increasing the rate of Ab clearance from the cerebrospinal fluid
(CSF) and brain are the common approaches of anti-Ab drugs
(Scheltens et al., 2016). At present, the complexity of AD's
pathogenesis is vaguely understood, which may involve
numerous other proteins beside Ab and various biological
pathways (Doig et al., 2017). This multifactorial AD
pathogenesis is most probably the main reason for the
repetitive failures of anti-amyloid drugs because a single target
treatment may not be able to cater for all the altered pathways
involved in the neurodegenerative events (Selkoe, 2019).
Initially, these anti-Ab agents show potential curative effects
through effective Ab clearance in CSF and the brain during the
early stage of drug development. However, the Ab level in mild-
to-moderate AD patients or even prodromal AD patients may
have reached the threshold of irreversible neurotoxicity, which is
the main reason for the failure of many anti-Ab drugs once
proceeded to phase III trials (Dobrowolska Zakaria and Vassar,
2018). This is probably due to lack of AD biomarkers in the past
to ensure early detection and recruitment of potential AD
patients for clinical trials (Folch et al., 2018b). Plus, Ab
plaques accumulate at a slow rate which may provide a large
time window for a potential intervention that could either
enhance the clearance or hinder the accumulation of Ab
insoluble proteins before brain atrophy and memory
impairment commences (Villemagne et al., 2013). According
to PET images taken by Vlassenko and colleagues, significant
changes in CSF Ab level and Ab deposition in the brain of AD
patients were reported, respectively 25 and 15 years prior to theTABLE 1 | Conventional available pharmacotherapy for Alzheimer's disease.
Drug Name Mechanism Dosage References
Tacrine AChE inhibitor • Oral q.i.d.: 10 – 20 mg (halted due to its hepatotoxicity) (Sameem et al., 2017)
(Lopes et al., 2018)
Donepezil AChE inhibitor Mild-to-moderate AD:
• Tablet q.d.: 5 mg, 10 mg
• Orally disintegrating tablet q,d,: 5 mg, 10 mg
Moderate-to-severe AD:
• Tablet q.d.: 10 mg,
• Orally disintegrating tablet q,d,: 10 mg
Severe AD:
• Tablet q.d.: 23 mg
(Masters et al., 2015)
(Foster et al., 2016)
(Zhang and Gordon, 2018)
(Birks and Harvey, 2018)
(Lee et al., 2015)
Rivastigmine AChE inhibitor Mild-to-moderate AD:
• Capsule b.i.d.: 1.5 mg, 3 mg, 4.5 mg, 6 mg
• Patch q.d.: 4.6 mg, 9.5 mg
Severe AD:
• Patch q.d.: 13.3 mg
(Birks and Evans, 2015)
(Chang et al., 2019)
Galantamine AChE inhibitor Mild-to-moderate AD:
• Tablet b.i.d.: 4 mg, 8 mg, 12 mg
• Solution b.i.d.: 4 mg
• Extended-release capsule q.d.: 8 mg, 16 mg, 24 mg
(Wake et al., 2016)
(Nakayama et al., 2017)
(Ohta et al., 2017)
(Blautzik et al., 2016)
(Oka et al., 2016)
Memantine N-methyl-D-aspartate receptor antagonist Moderate-to-severe AD:
• Tablet b.i.d.: 5 mg, 10 mg
• Solution b.i.d.: 2 mg/ml
• Extended-release capsule q.d.: 7 mg, 14 mg, 21 mg, 28 mg
(Wong et al., 2016)
(Schmitt et al., 2018)
(Deardorff and Grossberg, 2016)
(Folch et al., 2018b)
(Knight et al., 2018)
(Kanasty et al., 2019)Marchq.i.d., four times a day; q.d., once a day; b.i.d., twice a day.2020 | Volume 11 | Article 261
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This finding suggested an optimal time for early intervention of
AD; hence, early treatment can be given to the presymptomatic
AD patients who should have been recruited for clinical trials
rather than symptomatic AD patients. This is mainly because
symptomatic AD patients usually have irreversible synaptic loss
and neuronal deaths. Therefore, better recruitment of patients
with earlier stage of neurodegeneration and more consistent
pathology underlying their AD to participate in clinical trials
may generate more beneficial clinical outcomes (Briggs
et al., 2016).
The targeted protein to minimize the generation of Ab42 is
b-secretase 1 (BACE1), which is involved in the first proteolytic
cleavage of the APP protein and also g-secretase which plays a
role in the second cleavage in order to produce the Ab42
protein.Verubecestat, a BACE1 inhibitor, was discontinued
from the phase III trial due to its lack of efficacy and
inability to establish a positive risk/benefit ratio towards
mild-to-moderate and prodromal AD patients, althoughFrontiers in Pharmacology | www.frontiersin.org 4significant reduction of Ab in the patients' CSF and brains
were achieved during the trial (Egan et al., 2018). This finding
emphasized that solely targeting amyloid may not be an
appropriate strategy in treating AD. Lanabecestat is a
selective BACE1 inhibitor with satisfying blood-brain barrier
(BBB) penetration, high potency and permeability, and slow
off-rate that is critical for its efficacy (Eketjall et al., 2016).
However, lanabecestat was discontinued from the trials due to
its unlikeliness to meet the primary end points in mild-to-moderate
and prodromal AD patients based on a recommendation from the
data monitoring committee (Panza et al., 2019). Meanwhile, a phase
II/III trial of a non-selective BACE1, atabecestat, was halted as the
benefit/risk ratio was no longer favorable due to chronic elevations
of liver enzymes observed during the trial (Taylor, 2018).
The clinical trial of semagacestat was rushed without a strong
foundation of knowledge on the compound's physiological,
structural, and functional properties (De Strooper, 2014). It
was even more perplexing when the trial of semagacestat
continued to the next phase without any significant resultsTABLE 2 | Failed clinical trials of anti-Ab drugs for the treatments of Alzheimer's disease.
Name Therapy Type Clinical
Trials
Cohort Reason of failure References
Solanezumab IgG1 humanized anti-
Ab mAbs
III Mild-to-
moderate AD
Lack of efficacy (Honig et al., 2018)
Bapineurumab IgG1 humanized anti-
Ab mAbs
III Mild-to-
moderate AD
Lack of efficacy (Salloway et al., 2018)
(Ketter et al., 2017)
Crenezumab IgG1 humanized anti-
Ab mAbs
II Mild-to-
moderate AD
Lack of efficacy,
Did not meet primary and secondary endpoint.
(Cummings et al.,
2018)
Gantenerumab IgG1 humanized anti-
Ab mAbs
III Prodromal AD Halted due to futility, no significant differences observed in primary
and secondary endpoint.
(Ostrowitzki et al.,
2017)
Aducanumab IgG1 humanized anti-
Ab mAbs
III Mild-to-
moderate AD
Lack of efficacy (Selkoe, 2019)
(Haeberlein et al.,
2018)
(Sevigny et al., 2016)
Tramiprosate Ab aggregation
inhibitor
II Lack of efficacy (Selkoe, 2011)
(Sabbagh, 2017)
(Kocis et al., 2017)
(Malouf and Collins,
2018)
Semagacestat g-secretase inhibitor III Lack of efficacy,
Worsens cognition function at higher doses,
High incidence of skin cancer and infections
(Doody et al., 2013)
(Henley et al., 2014)
Verubecestat BACE1 inhibitor III Mild-to-
moderate AD
Prodormal AD
Lack of efficacy,
Adverse events:
Occurrence of rash
Changes in hair color
Tend to have more falls and injuries
Weight loss
Sleep disturbance
Suicidal ideation
(Egan et al., 2018)
(Kennedy et al., 2016)
Lanabecestat BACE1 inhibitor III Early AD
Mild-to-
moderate AD
Unlikely to meet primary endpoint, stopped for futility (Eli Lilly and
Company, 2018)
(Cebers et al., 2017)
(Eketjall et al., 2016)
Atabecestat BACE1 inhibitor II/III Early AD Adverse events:
Elevation of liver enzymes
(Timmers et al., 2018)
(Taylor, 2018)
(Janssen, 2018)
Avagacestat g-secretase inhibitor II Prodromal AD Lack of efficacy
Adverse events:
Weight loss
Glycosuria
(Coric et al., 2015)March 2020 | Volume 11 | Article 261
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of phase III trial. The drug was not even as effective as the
placebo, aggravated cognitive deterioration at higher doses, and
demonstrated high incidence of skin cancer and infections in the
study group (Doody et al., 2013). The drug's adverse effects may
potentially be linked to the altered Notch signaling pathway,
where Notch was one of the alternate substrates for g-secretase,
important for cell differentiation. Blocking g-secretase through
semagacestat may have blocked the differentiation of cells vital
for the immune system, pigmentation, and gastrointestinal
functions such as B and T lymphocytes, melanocyte stem cells,
and gastrointestinal epithelial cells (Henley et al., 2014). The loss
of Notch signaling by semagacestat may trigger mutations
responsible for the development of skin cancer in patients'
groups receiving semagacestat (Nowell and Radtke, 2017).
Apart from that, tramiprosate was an anti-glycosaminoglycan
compound that targeted the inhibition of Ab aggregation studied
until the phase II trial (Folch et al., 2018b). Ab binds with
glycosaminoglycan on the cell surface for cellular uptake and
internalization depending on the electrostatic interaction
between the positively charged Ab and negatively charged
sulfate residue on the glycoaminoglycan (Stopschinski et al.,
2018). Tramiprosate was also withdrawn from the trial due to
a lack of consistent cognitive improvement as measured in
Alzheimer's Disease Assessment Scale-cognitive subscale
(ADAS-Cog) (Aisen et al., 2011). Nevertheless, tramiprosate
was found to have higher efficacy to apolipoprotein E4
homozygotes in AD patients. Therefore, a thorough molecular
analysis elucidated the mechanism of action of tramiprosate in
aggregate Ab42 that may be advantageous for further
development of tramiprosate as an AD therapeutic regimen
(Sabbagh, 2017). Concisely, tramiprosate prevents the
misfolding of self-assembled Ab42 monomers by enveloping
them, thereby hindering the aggregation of neurotoxic Ab42
plaques (Kocis et al., 2017).
Besides, extensive development of Ab humanized IgGI
monoclonal antibodies agents, such as solanezumab and
bapineuzumab, that targeted the central epitopes of soluble Ab
monomers and the N-terminus of Ab42 were also halted due to a
lack of efficacy in mild-to-moderate AD patients (Honig et al.,
2018; Castellani et al., 2019). After repetitive failures in phase III
clinical trials in mild-to-moderate AD patients, EXPEDITION 1,
EXPEDITION 2 and EXPEDITION 3, solanezumab are
currently being tested in asymptomatic and mildly
symptomatic patients with biomarker evidence of Ab plaques
deposition in brains as a preventive strategy towards AD (Willis
et al., 2018). A combined therapy of solanezumab and
gantenerumab was also terminated due to their lack of clinical
advantages and apparent side effects when combined with
BACE1 inhibitor (Cummings et al., 2019). The combination
therapy was initiated to enhance the immune response towards
Ab plaques, hence, promoting Ab clearance while BACE1
inhibits the generation of new Ab (Folch et al., 2018b).
Nonetheless, there are two emerging anti-Ab oligomers
monoclonal antibodies with promising efficacy, aducanumab
and BAN2401, that bind to insoluble fibrils and soluble AbFrontiers in Pharmacology | www.frontiersin.org 5protofibrils, thus, relieving the brains' Ab burden with positive
impact on cognition (Panza et al., 2019). Aducanumab is an Ab-
targeting monoclonal antibody that is currently showing
significant dose-dependent reduction of Ab plaques' size
(Haeberlein et al., 2018). Besides binding to both forms of Ab,
soluble oligomers and insoluble fibrils, aducanumab also
alleviates calcium dyshomeostasis in affected neurons, since
neuronal calcium was found altered in AD brains (Gamage
and Kumar, 2017). Further studies should investigate whether
the alleviation of elevated intracellular calcium by aducanumab
plays a role in restoring the cognitive functions in AD. In a phase
III trial, aducanumab failed to slow down cognitive deterioration
in mild-to-moderate patients due to reasons such as the patients
were irreversibly symptomatic, targeting Ab was not sufficient as
it may have already caused irreversible synapse and microglia
toxicity, and multifactorial ADmay require combination therapy
(Selkoe, 2019).
BAN2401 is a humanized monoclonal antibody with
encouraging therapeutic effects in treating AD. The drug is
highly selective to Ab protofibrils and recedes the formation of
Ab plaques, causing a 30% delay to cognitive impairment in
mild-to-moderate AD patients within 18 months and a 47%
delay by the highest dose in a phase II trial (Swanson et al., 2018).
However, future studies should explore the potential of this drug
in a larger group (Mendes and Palmer, 2018; Panza et al., 2019).
Passive immunization is the most predominant therapeutic
approach in targeting Ab where exogenous monoclonal
antibodies (mAbs) are administered to the patients. However,
this approach has been weighted with repetitive failures that
subsequently theorized several augmentations for the anti-Ab
mAbs development (Piton et al., 2018). Firstly, mAbs targeting
the N-terminus of Ab are highly potent in suppressing the
aggregation of Ab and disaggregating the pre-existing Ab
fibrils (van Dyck, 2018). Next, better penetration through the
BBB and higher doses of mAbs may be tested in the future since
mAbs have astonishing safety profiles. Finally, recruiting
preclinical AD patients for the prevention of AD clinical trials
is one of the initiatives taken to maximize the benefits of anti-Ab
mAbs in treating AD at an early stage (Hampel et al., 2010).EMERGING TREATMENTS:
NEUROINFLAMMATION
Recently, the drive for new therapeutic strategies has focused on
neuroinflammation interceded by microglia and astrocytes in
AD pathogenesis, rather than the accustomed AD hypotheses
such as Ab and tau pathologies. This has resulted in extensive
investigations of anti-inflammatory and antioxidant agents
(Heneka et al., 2015). In a healthy brain, microglia provide
protection against exogenous insult, while astrocytes furnish
nutritional and structural support for neurons (Van Eldik
et al., 2016). At the early stages of AD, excessive deposition of
extracellular Ab plaques and continuous activation of glial cells
cause the release of inflammatory cytokines such as interleukin-
1a (IL-1a), tumor necrosis factor-a (TNF-a), and complementMarch 2020 | Volume 11 | Article 261
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expression of insulin-degrading enzyme (IDE) for Ab
degradation and signal for neuronal apoptosis (Son et al.,
2016). NFkB signaling cascades enhanced in glial cells of AD
brain to produce various inflammatory and immune proteins,
including compliment component 3 (C3) that initiates neural
destruction through complement-mediated synapse pruning
when it binds to C3a receptors on a neuron (Benarroch, 2018).
Constant production of inflammatory cytokines by microglia
leads to neuroinflammation and synaptic loss. Neuroinflammation
suppresses the phagocytosis of Ab plaques which may aggravate
neurodegeneration (Cianciulli et al., 2020). Despite the undefined
mechanism of rilapladib, it is presumed that rilapladib reduces
neuroinflammation through the reduction of proinflammatory
cytokines and restoration of BBB integrity (Maher-Edwards et al.,
2015; Huang et al., 2020).
Microglia are activated into disease-associated microglia
(DAM) through triggering receptors expressed on myeloid
cells 2 (TREM2) independent and dependent pathways during
the microglia-Ab plaques interaction, which facilitate Ab plaques
phagocytosis and suppresses overproduction of inflammatory
cytokines (Keren-Shaul et al., 2017). Activation of TREM2 leads
to the phosphorylation of immunoreceptor tyrosine-based
activation motif (ITAM) that causes the spleen tyrosine kinaseFrontiers in Pharmacology | www.frontiersin.org 6(SYK) to dock within the receptor complex and activates the
phosphatidylinositol 3-kinase (PI3K) cascades (Zheng et al.,
2018). The initial response following the activation of PI3K
pathway was to produce pro-inflammatory cytokines as a
neuroprotective feedback (Cianciulli et al., 2016). Several
studies reported that mutations of TREM2 in AD reduced the
phagocytic capacity of DAM, disrupted the downstream PI3K
pathway, and impaired suppression of pro-inflammatory
cytokines released by the glial cells (Jay et al., 2017; Achebe
et al., 2018). Meanwhile, overexpression of TREM2 ameliorated
neuroinflammation by inhibiting the pro-inflammatory
responses initiated by microglia (Ren et al., 2018).
In addition, restoring the microglia function in Ab clearance
may open new doors for the development of AD treatments
through inhibiting receptor-interacting serine/threonine protein
kinase 1 (RIPK1) that are highly expressed in microglia of AD
brains (Mullard, 2018). Inhibition of RIPK1 reduces the
overexpression of Cst7 that encodes for cystatin F, an
endosomal/lysosomal cathepsin inhibitor, which reduces the
phagocytic capacity of primary immune cells (Ofengeim et al.,
2017). Therefore, RIPK1 inhibitor is suggested to encounter
neuroinflammation caused by inflamed microglia that disrupts
the phagocytosis of toxic dead cells by reducing the expression of
Cst 7 and escalating Ab plaques clearance.FIGURE 1 | Neuroinflammation in Alzheimer's disease. Ab plaques, NFTs and oxidative stress dysregulate various signaling cascades, causing neuroinflammation,
and eventually neurodegeneration. Multiple novel pharmacotherapies ameliorate AD by normalizing the dysregulated signaling pathways in AD. IDE, insulin-degrading
enzyme; Ab, amyloid beta; IL-1a, interleukin 1a; TNF-a, tumour necrosis factor-a; C3, complement component 3; C1q, complement protein 1q; TREM2, triggering
receptor expressed on myeloid cells 2; ITAM, immunoreceptor tyrosine-based activation motif; SYK, spleen tyrosine kinase; P, phosphate; PI3K, phosphatidylinositol
3-kinase; NFkB, nuclear factor kappa b; RIPK1, receptor-interacting serine/threonine-protein kinase 1; Cst7, cystatin F gene; RTK, receptor tyrosine kinase; PDK1,
phosphoinositide-dependent kinase 1; mTOR, mammalian Target of Rapamycin; Akt, protein kinase B; GSK-3b, glycogen synthase kinase 3b; TSC, tuberous
sclerosis complex; AMP, adenosine monophosphate; AMPK, AMP-activated protein kinase; SIRT1, silent information regulator type 1; BACE1, b-secretase 1; cAMP,
cyclic adenosine monophosphate; PKA, protein kinase A; CREB, cAMP response element binding protein; NMDAR, NMDA receptor; Ca²⁺/Calmodulin-dependent
protein kinase II (CAMKII); LIMK1, LIM kinase 1; BDNF, brain-derived neurotrophic factor. Asterisk (*) in the diagram indicates uncertain changes of activity in AD.March 2020 | Volume 11 | Article 261
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progression of many CNS-related complications (Kumar et al.,
2018a; Kumar et al., 2018b). Ab plaques cause glutamatergic
hyperexcitation through continuous stimulation of NMDAr that
results in its desensitization and an increase in Ca2+ influx
(Wang X. P. et al., 2019). NSAIDs such as diclofenac and
rofecoxib were said to be a potential strategy in combating
neuroinflammation by regulating Ca2+ homeostasis, tau
phosphorylation, axonal growth, and astrocyte motility
through Rho-GTPases pathway (Kumar et al., 2015). The
binding of Ca2+ with calmodulin forms Ca2+/Calmodulin
complex, which subsequently activates Ca²⁺/Calmodulin-
dependent protein kinase II (CAMKII) and Rho-GTPases
pathway, which is important for in spine morphogenesis
during the induction of long-term potentiation (LTP) (Luo
et al., 2016). LIM kinase 1 (LIMK1), a downstream kinase in
Rho-GTPases pathway, phosphorylates and inhibits cofilin, a
protein involved in the depolymerization of f-actin (Fan et al.,
2018). Ab was reported to disrupt the Rho-GTPases pathway,
which regulates the dynamic of polymerization and
depolymerization of f-actin to maintain the neurons'
morphology (Ferrera et al., 2017). Meanwhile, ibuprofen was
shown to phosphorylate cofilin at S3 to inhibit cofilin, thus,
preventing the depolymerization of f-actin and impairment of
synaptic plasticity. Besides, NSAIDs also suppress the microglial
activation and lessen the accumulation of activated microglia
(O'Bryant et al., 2018). But, NSAIDs tend to cause toxicity due to
its non-selective activity. In addition, rofecoxib, a specific
cyclooxygenase-2 (COX-2) inhibitor was studied in AD as
COX-2 mRNAs were upregulated in AD brains (Wang et al.,
2015). Inhibiting COX-2 may also hinder the decline of LTP
provoked by the deposition of Ab in the hippocampus (Deardorff
and Grossberg, 2017).
Besides, phenolic compounds with antioxidant properties
such as oleuropein and epigallocatechin gallate (EGCG) are
also of interest for early intervention in AD management
(Kamil et al., 2018). This is mainly because a significant
deficiency in brain antioxidant levels was identified as the
oxidative stress marker in AD (Sharman et al., 2019). For
instance, EGCG was said to suppress the Ab plaque-induced
upregulation of proinflammatory cytokines in microglia, and
also upregulate the expression of endogenous antioxidants such
as nuclear arythroid-2 related factor 2 (Nrf2) and heme
oxygenase-1 (HO-1). Hence, EGCG elicits a protective effect
against oxidative stress and neuroinflammation (Cheng-Chung
Wei et al., 2016).NOVEL PHARMACOLOGY: MOLECULAR
TARGETS
Development of novel AD pharmacotherapy is becoming profoundly
important as the complexity of AD pathogenesis becomes better
understood in recent times, resulting in the exploration of multitude
targets in AD therapeutic strategies (Table 3). The pipeline of AD
treatments is augmented with compounds that either modify theFrontiers in Pharmacology | www.frontiersin.org 7underlying AD pathophysiology, target several molecular targets
synergistically, or repurposed as an anti-Alzheimer's drug (Bachurin
etal., 2017).
Other potential treatments for AD include those based on the
inhibition of glycogen synthase kinase-3b (GSK-3b) and
mammalian target of rapamycin (mTOR) to attenuate
neuroinflammation by increasing Ab clearance and decreasing
tau phosphorylation (Modrego and Lobo, 2019). Normally,
extracellular ligands bind to a receptor tyrosine kinase (RTKs),
which activate PI3K signaling cascades and lead to the activation
of PDK-1 and Akt. PDK1 also indirectly activates the mTORC2
complex which activates Akt through the phosphorylation of the
kinase at S473 and S450. Active Akt phosphorylates and activates
tuberous sclerosis complex (TSC) 1 and 2, a negative regulator of
mTORC1 (Hermida et al., 2017). mTOR inhibition activates the
ubiquitin proteasome system and autophagy. In AD brain, where
PI3K/Akt signaling pathway is downregulated due to Ab
plaques-induced neurotoxicity, Akt is suppressed and
mTORC1 activity is increased, which disrupts cell autophagy,
leading to neuroinflammation (Shal et al., 2018). Wang and
colleagues reported rapamycin's (mTORC1 inhibitor) ability to
inhibit elevated activation of mTORC1 and pro-inflammatory
cytokines in the hippocampus of AD rats (Wang et al., 2016).
Suppressed Akt also promotes activation of GSK-3b to cause
hyperphosphorylation of tau that aggregates to form NFTs once
detached from the microtubules. The loss of microtubules'
integrity induces neuroinflammation and increases the risk of
neuronal death (Mancinelli et al., 2017).
Methylene blue (MB) is one of the anti-tau disease modifying
agents (DMTs) that combats tau pathology through two
molecular targets: GSK-3b and tau aggregation (Gandini et al.,
2018). Hyperphosphorylation of tau is associated with the loss of
counterbalance between the kinases and phosphatases involved
in tau phosphorylation, especially if the phosphorylation takes
place at the sites of kinases as this family of enzymes regulate
most of the protein function (Pradeepkiran et al., 2019). Kinases
involved in tau phosphorylation are mitogen-activated protein
kinases (MAPKs), cyclin-dependent kinases (Cdks), GSK-3b,
and protein kinase A (PKA) (Kheiri et al., 2018; Li et al., 2018).
Initially, MB was well-known for its inhibiting activity on tau
aggregation in AD clinical trials (Gureev et al., 2019). In spite of
the advance in knowledge on tau pathology, partial inhibition on
tau aggregation by MB is not adequate to halt AD as the
underlying event that causes tau-mediated neurotoxicity is the
binding of granular tau oligomers during NFT formation (Soeda
et al., 2019).
Binding of Ab plaques or glutamate to synaptic receptors can
initiate the production of cyclic adenosine monophosphate
(cAMP) from adenylyl cyclase, activating the cAMP/PKA
pathway. Under normal conditions, downstream cAMP/PKA
pathway results in phosphorylation of transcription factors such
as cAMP response element binding protein (CREB) at S133,
which stimulates transcription and translation of genes involved
in the formation of memory (Bartolotti et al., 2016; Gao et al.,
2018). However, the level of p-PKA was significantly decreased
in the hippocampus of AD mice while neuroinflammation wasMarch 2020 | Volume 11 | Article 261
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Name Mechanism Clinical trials References
Masatinib
(AB1010)
GSK-3b Inhibitor
Tyrosine kinase inhibitor target mast cells and
macrophages.
Phase II/III trial on mild-to-moderate AD patients
Escalated dose: 4.5 mg/kg/day b.i.d., escalate to 6 mg/kg/day
after 3 months' treatment
Fixed dose: 4.5 mg/kg/day b.i.d. and 3.0 mg/kg/day b.i.d.
Primary endpoint:
1. ADCS-ADL that indicates self-care and activities of daily living
2. ADAS-Cog that measure the effect on cognition and memory
Secondary endpoint:
1. MMSE
2. CIBIC-plus
(Palomo et al.,
2017)
(AB Science
SA, 2019)
(Folch et al.,
2015)
Methylene blue (MB)
NCT02380573
Inhibit the formation of tau oligomers Phase II clinical trial on healthy aging, mild cognitive impairment
(MCI), and mild AD patients
Primary endpoint:
1. Working memory task
2. Working memory task response
3. Episodic memory task
4. Episodic memory response
5. Sustained attention task
6. Neurological battery composite score
Secondary endpoint:
1. Cerebral blood flow measures
(Cummings
et al., 2019)
(Soeda et al.,
2019)
(Gauthier et al.,
2016)
Metformin
NCT01965756
Biguanide class medication
Decrease insulin level that affect the clearance of Ab in
brain
Decrease advanced glycation end products and
inflammation in AD
Phase II clinical trial on MCI and early AD patients
Metformin > Placebo
oral metformin for 8 weeks (500 mg q.d. for 1 week, increased
dose by 500 mg per week until a maximum dose of 2000 mg per
day), followed by 8 weeks of placebo
Placebo > Metformin
After 8 weeks of placebo, oral metformin for 8 weeks (500 mg q.d.
for 1 week, increased dose by 500 mg per week until a maximum
dose of 2000 mg per day)
Primary endpoint:
1. Word List Memory Total (ADAS-cog)
Secondary endpoint:
1. Trails-B
(Ou et al.,
2018)
(Luchsinger
et al., 2016)
(Campbell
et al., 2017)
(Weinstein
et al., 2019)
RPEL Improve inhibition of AChE, reduce Ab aggregation and
reduce phosphorylation of tau
In vivo and in vitro studies (Sergeant
et al., 2019)
Tideglusib
NCT01350362
Thiadiazolidinone acts as an GSK-3b inhibitor, reduce tau
phosphorylation and prevent neurons apoptosis.
Anti-inflammatory
Phase II clinical trial on mild-to-moderate AD patients for 26 weeks
Oral tideglusib 1000 mg q.d. Oral tideglusib 1000 mg.q.o.d. once
every other day
Oral tideglusib 500 mg q.d. Placebo q.d.
Primary endpoint: ADAS-Cog+
(Del Ser et al.,
2013)
(Wang and
Mandelkow,
2016)
Elenbecestat
NCT03036280
BACE1 inhibitor that inhibit BACE1 involved in amyloid
precursor protein (APP) proteolytic cleavage during the
formation of Ab
Phase II clinical trial on prodromal AD and mild-to-moderate AD
patients
Phase III clinical trial on early AD patients
Dosage:
50 mg q.d in the morning
MissionAD1 and MissionAD2 - Phase III trial on early AD with
positive biomarkers for brain amyloid pathology.
Primary endpoint: CDR-SB
Contact dermatitis, upper respiratory infection, headache, diarrhea,
fall and dermatitis.
(Folch et al.,
2018b)
(Panza et al.,
2018)
BAN2401
NCT03887455
IgG1 humanized anti-Ab mAbs that binds selectively to Ab
protofibrils.
Phase III clinical trial on early AD patients
Dosage: 10 mg/kg i.v. BAN2401 biweekly
Primary endpoint:
1. Change on CDR-SB from baseline
2. Number of participants with treatment-emergent adverse
events (TEAEs)
Secondary endpoint:
1. Change on amyloid Positron Emission Tomography (PET) from
baseline
2. Change on ADCOMS from baseline
3. Change on ADAS-cog 14 from baseline
(BioArctic AB
and Eisai Co.,
2019)
(Swanson
et al., 2018)
(Logovinsky
et al., 2016)
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CT1812
NCT03522129
Lipophilic isoindoline that bind allosterically to sigma-2
receptor complex and destabilize the Ab oligomers binding
at synapses' neuronal receptors.
Phase I clinical trial on mild-to-moderate AD patients
Dosage: 90 mg, 280 mg, 560 mg CT1812
Primary endpoint:
1. Displacement of Ab oligomers into CSF
(Grundman
et al., 2019)
(Catalano
et al., 2017)
Nilotinib
NCT02947893
Inhibit brain Ab,
Decrease Ab and pTau
Modulate brain and peripheral immune profiles
Reverse cognitive decline in AD
Phase II clinical trial on mild-to-moderate AD patients
Dosage: oral 150 mg/capsule nilotinib q.d, 2 capsules after 6
months of 1 capsule
Primary endpoint:
1. Number of participants with adverse events/abnormal
laboratory values
(Weinstein,
2018)
(Pagan et al.,
2016)
(Nishioka et al.,
2016)
Acitretin
NCT01078168
a-secretase enhancer/amyloid aggregation inhibitor,
Retinoic acid receptor agonist
Phase II clinical trial on mild-to-moderate AD patients
Dosage: oral 30 mg q.d.
Primary endpoint:
1. Difference in soluble alpha-cleaved APP in CSF
(dos Santos
Guilherme
et al., 2019)
(Freese et al.,
2014)
Pinitol(NIC5-15)
NCT00470418
a-secretase inhibitor that is Notch sparing Phase II clinical trial on AD patients
Primary endpoint:
1. Number of participants with adverse events
(Anandakumar
et al., 2018)
(López-
Sánchez et al,
2018)
Bryostatin
NCT02431468
a-secretase enhancer, PKC modulator –
immunomodulatory effect, increase cognitive ability
Phase II clinical trial on moderately severe-to-severe AD patients
Dosage: 20 & 40 mg Bryostatin, i.v.
Primary endpoint:
1. Number of participants with TEAE and SAE
2. Change in Severe Impairment Battery (SIB) in the Full Analysis
Set (FAS)
Secondary endpoint:
1. SIB
2. ADCS-ADL-SEV
3. MMSE-2
4. NPI
5. CGI-I
(Farlow et al.,
2019)
Bexarotene
NCT01782742
Retinoid X receptors (RXR) agonist to reduce Ab in the
brain
Phase II clinical trial on mild-to-moderate AD patients
Dosage: 75 mg of bexarotene b.i.d., 150 mg after 1 week
Primary endpoint:
1. Change in brain amyloid burden measured by standard uptake
unit regional (SUVr) according to genotypes involved in this trial
Secondary endpoint:
1. MMSE
2. ADAS-cog
3. CDR
4. NPI
5. ADCS-ADL
6. Serum Ab1-42 level
7. Ratio of Ab42 to Ab40 in non-ApoE4 carriers
(Cummings
et al., 2016)
ELND005 (formerly
known as AZD-103),
scyllo-inositol
NCT01735630
Inhibit the build-up of amyloid protein in AD brains Phase II clinical trial on moderate-to-severe AD patients
Dosage: ELND005 tablets, b.i.d. for 12 weeks
Primary endpoint:
1. Change in NPI-C combined agitation and aggression
Secondary endpoint:
1. ADCS-CGIC
2. NPI
3. MMSE
4. ADCS-ADL
(Lee et al.,
2017)
ABT-354
NCT01908010
5-HT6 antagonist regulate the release of acetylcholine,
glutamate and noradrenaline in the forebrain region.
Phase I clinical trial on mild-to-moderate AD patients
Primary endpoint:
1. Vital signs
2. ECG
3. Neurological exam
4. Laboratory tests (hematology, chemistry, urinalysis)
5. Number of participants with adverse events
6. C-SSRS
(Ferrera et al.,
2017)
(Lalut et al.,
2017)
(Continued)Frontiers in Pharmacology | www.frontiersin.org March 2020 | Volume 19 1 | Article 261
Ibrahim et al. Pharmacotherapy of Alzheimer’s DiseaseTABLE 3 | Continued
Name Mechanism Clinical trials References
Secondary endpoint
7. Pharmacokinetic parameters
CNP520
NCT03131453
BACE1 Inhibitor Generation Study 2 – Phase II/III trial on homozygotes APOE ϵ4
and heterozygotes APOE ϵ4 carriers with elevated brain amyloid.
Dosage: p.o. 15 mg/day or 50 mg/day CNP520
Primary endpoint:
1. diagnosis of MCI
2. APCC test score.
(Lopez et al.,
2019)
(Panza et al.,
2018)
(Borowsky
et al., 2019)
Crenezumab
NCT02670083
Amyloid monoclonal antibodies Phase III clinical trial on prodromal to lid AD patients
Dosage: i.v. crenezumab q4w for 100 weeks
Primary endpoint:
1. Change in CDR-SB
(Cummings
et al., 2018)
Rilapladib
NCT01428453
Lipoprotein-associated phospholipase A2 (Lp-PLA2)
inhibitor that suppress neuroinflammation
Phase IIa clinical trial on AD patients
Dosage: 250 mg rilapladib
Primary endpoint: Change in
1. Ab42 and Ab40 level in CSF
2. Ratio of Ab42/Ab40 in CSF
3. Tau and p-tau in CSF
4. Working memory/executive function (WM/EF) composite score
(Maher-
Edwards et al.,
2015)
Edonerpic Maleate
(T-817MA)
NCT02079909
Activate sigma-1 receptor and regulate the microglial
function.
Phase II clinical trial on mild-to-moderate AD patients
Dosage: 224 mg of T-817MA q.d., 448 mg after 4 weeks
Primary endpoint: Change in
1. ADAS-cog
2. CGIC
Secondary endpoint:
1. ADCS-ADL
(Schneider
et al., 2019)
Carvedilol
NCT01354444
Non-selective B-adrenergic receptor blocker that indirectly
reduce neurons' apoptosis.
Phase IV clinical trial on AD patients
Dosage: 25 mg of carvediol daily
Primary endpoint:
1. Hopkins Verball Learning Test (HVLT)
Secondary endpoint:
1. Ab oligomers level in CSF
(Liu and Wang,
2018)
Intepirdine (RVT-101)
NCT02585934
5-HT6 antagonist Phase III clinical trial on AD patients
Dosage: 35 mg of oral RVT-101 q.d.
Primary endpoint: Change in
1. ADAS-cog 11
2. ADCS-ADL
Secondary endpoint:
1. CIBIC+
2. Dependence Scale (DS)
3. Neuropsychiatric Inventory (NPI)
4. ADAS-cog 13
5. Plasma concentration of RVT-101
(Lombardo
et al., 2017a)
(Lombardo
et al., 2017b)
(Zhu et al.,
2017)
Vanutide Cridificar
(ACC-001)
NCT00479557
Vaccine that produce Ab-directed B-cell response. Phase II clinical trial on mild-to-moderate AD patients
Dosage: 3, 10, 30 mg IM on day 1, month 1, 3,6, and 12
Primary endpoint:
1. Percentage of participants with treatment-emergent adverse
events (TEAEs) or serious adverse events (SAE)
Secondary endpoint:
1. Geometric mean titers (GMTs) of Anti-Ab immunoglobulin (IgG)
using Enzyme-linked Immunosorbent Assay (ELISA)
(Pasquier
et al., 2016)
Resveratrol
NCT01504854
SIRT1 potent activator acts as anti-inflammatory Phase II clinical trial on mild-to-moderate AD patients
Dosage: 500 mg oral resveratrol q.d.
Primary endpoint:
1. Number of adverse events
2. Change from baseline on volumetric magnetic resonance
imaging (MRI)
Secondary endpoint:
1. ADCS-ADL
2. CSF Ab level
(Drygalski
et al., 2018)
(Moussa et al.,
2017)
(Turner et al.,
2015)Frontiers in Pharmacology | www.frontiersin.org 1 March 2020 | Volume 10 1 | Article 261
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subsequently decreased the phosphorylated CREB in the rats'
hippocampus (Huang et al., 2019). High levels of BACE1 in AD
brain inhibits adenylyl cyclase and impairs cAMP/PKA pathway,
which interrupts the phosphorylation and eventually disrupts the
transcription and translation of CREB-induced genes, leading to
memory impairment in AD (Chen et al., 2012). CREB activation
can restore memory impairment in AD as the CREB-induced
genes, such as brain-derived neurotrophic factor (BDNF) and
insulin-like growth factor 1, can enhance neuron morphological
outgrowth and formation of long-term and short-term memories
(Kubota et al., 2017).
Metformin is a first-line medication for type 2 diabetes, which was
repurposed for AD treatment as it exhibits anti-inflammatory
properties and neuroprotective features against cognitive
deterioration in AD (Ou et al., 2018). Metformin hinders the
neuronal apoptosis and promotes neurogenesis in the hippocampus
through the activation of the AMP-activated protein kinase (AMPK)
pathways, which leads to the improvement of memory formation.
AMPK can be phosphorylated by 3 key kinases, such as the liver
kinase B1 (LKB1) complex at T172, due to increased cytoplasmic level
of AMP, increased cytosolic Ca2+, and mitogen-activated protein
kinase 7 (MAP3K7), also known as transforming growth factor beta-
activated kinase 1 (TAK1) (Wang X. et al., 2019). AMPK also
activates TSC1/2 complex that inhibits mTOR (Wang X. et al.,
2019). Activity of AMPK was decreased in the hippocampus of AD
rats at age 4-5 months, while the activity of mTOR increased, causing
disrupted cell autophagy and exacerbated AD (Du et al., 2015; Sun
et al., 2019). Inhibition of mTOR by rapamycin restores normal cell
autophagy and protein synthesis (Sun et al., 2018).
PKA was found to activate silent information regulator type 1
(SIRT1), a neuroprotective protein deacetylase that reduces tau
acetylation and downregulates BACE1, hence, increasing
degradation of tau and reducing Ab production (Zhang et al.,
2019; Wang X. et al., 2019). Resveratrol, through activation of
SIRT1, reverses the drastic decrease in hippocampal expression
of SIRT1 in AD (Turner et al., 2015; Hou et al., 2017). Resveratrol
was also found to reduce neuronal apoptosis and eventually
restore cognitive impairment in AD (Tian et al., 2016).
Current DMTs target either Ab pathology or tau pathology,
which may be the reason for their lack of efficacy since both
pathologies synergistically cause cognitive degeneration with the
cholinergic deficit as a constant concern in AD. Multi target-
directed ligand (MTDLs) is a novel approach to surmount the
multifactorial AD pathogenesis (Geldenhuys and Darvesh,
2015). RPEL was synthesized through the combination of N,
N'-disubstituted piperazine anti-amyloid scaffold and tacrine,Frontiers in Pharmacology | www.frontiersin.org 11into one compound (Sergeant et al., 2019). It was found effective
in preventing cognitive impairment as it minimizes the Ab
plaques formation and tau phosphorylation in AD mice
without any adverse effect besides maintaining the inhibitory
activity on AChE. This approach accelerates the development of
potential treatment for AD by minimizing the cost and time
since the individual therapeutic effects of each compound is
generally known (Hassan et al., 2019).CONCLUSION
Despite decades of research, we are still encountering a lack of
success in pharmacotherapy of AD, mostly due to the
multifactorial etiologies of the disorder that can initiate
neurodegeneration interdependently. At present, combination
therapy targeting several factors simultaneously appears to be
promising. Additionally, an increasing number of studies are also
focusing on neuroprotection against neuroinflammation. The
impact of neuroinflammation interceded by microglia and
astrocytes in AD pathogenesis is of great interest as it opens
new doors for novel therapeutic targets. In addition to
pharmacotherapy, better prognosis through early detection of
AD biomarkers or brain imaging will enable early intervention
that could potentially prevent the deposition of Ab plaques and
manifestations of various irreversible symptoms of AD.AUTHOR CONTRIBUTIONS
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